The major findings from this exploratory phase II trial on FG001, was that a novel uPAR-targeting NIR imaging agent allows tumor-specific and safe real-time in-vivo and ex-vivo imaging of oral and oropharyngeal cancer. Here, PLAUR is linked to oropharynx cancer.